FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Deficiencies in CM and RTRT-D NDA Submissions

[ Price : $8.95]

Three CDER researchers share best practices to reduce deficiencies in regulatory submissions involving real-time release testing f...

Multiple Denison Pharmaceuticals Violations

[ Price : $8.95]

FDA warns Lincoln, RI-based Denison Pharmaceuticals about CGMP violations and manufacturing unapproved new drugs.

CDRH Prefers Guidance Comments in Table Format

[ Price : $8.95]

A new CDRH Web page on tips for providing stakeholder comments on guidance documents says the Center prefers comments that are sub...

CathVision Electrophysiology Algorithms Cleared

[ Price : $8.95]

FDA clears a CathVision 510(k) for the PVI Analyzer and Signal Complexity algorithms as part of the companys electrophysiology rec...

AstraZeneca Gets 1st OPDP 2023 Warning Letter

[ Price : $8.95]

The CDER Office of Prescription Drug Promotion warns AstraZeneca that a sales aid for its Breztri misrepresents the drugs efficacy...

Informed Consent Guidance

[ Price : $8.95]

FDA publishes a guidance on the roles of IRBs, clinical investigators, sponsors, and FDA in informed consent for clinical investig...

QS Violations at TEI Biosciences

[ Price : $8.95]

FDA warns Boston, MA-based TEI Biosciences about Quality System violations in its manufacturing of collagen-based products.

Hold Lifted on Arcellx Myeloma Drug

[ Price : $8.95]

FDA removes a partial clinical hold against an Arcellx IND for CART-ddBCMA, an investigational drug for treating patients with rel...

FDA Approves Hepzato for Uveal Melanoma

[ Price : $8.95]

FDA approves Delcath Systems Hepzato Kit (melphalan for injection/hepatic delivery system) for liver-directed treatment in adult p...

Info Collection Revision on BLA Procedures

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection revision entitled Biologics License Applications (BLAs) Proced...